ClinicalTrials.gg
RecruitingNCT05105633POST-ETERNALUpdated May 6, 2026

Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke

A Phase 2/3 interventional study of Tenecteplase and Standard Care (which may include intravenous Alteplase) in Basilar Artery Occlusion, sponsored by University of Melbourne. Recruiting at 17 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by University of Melbourne · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
688
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies testing tenecteplase in Ischemic Stroke — 32 open to participants now, 32 under way, 25 of them phase 3. Tenecteplase · Ischemic Stroke.

Planned enrollment
20th of 59
688 · median 466
Started
2021
with 3 others
Phase 2/3
6 of 59
2 open now
Primary completion
2028-05
later than 19 of 31 live
Registered
16th of 59
by date
Lead sponsor
2 of 59
University of Melbourne

Among the 59 studies testing tenecteplase in Ischemic Stroke, this one is the 20th largest by planned enrollment, is one of 4 that started in 2021, is one of 6 in phase 2/3, reaches primary completion later than 19 of the 31 other live ones, and was the 16th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

32 of the 59 studies testing tenecteplase in Ischemic Stroke are open now, in 12 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About tenecteplase

Tenecteplase: first FDA approval 2000 (TNKASE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing tenecteplase in Ischemic Stroke, or all of them as a file.
02

Study summary

Patients presenting to the emergency department with an acute ischemic stroke due to basilar artery occlusion within 24 hours of stroke onset will be assessed to determine their eligibility for randomization into the trial. If the patient gives informed consent they will be randomised 50:50 using a central computerised allocation process to either standard of care (no intravenous thrombolytic treatment or intravenous alteplase 0.9mg/kg) or tenecteplase 0.25mg/kg before undergoing mechanical thrombectomy as required at treating clinician's discretion. The trial is Multi-arm, Multi-stage, prospective, randomised, open-label, blinded endpoint (PROBE) design with seamless phase 2b/3 transition if the intermediate endpoint (recanalization without symptomatic intracerebral hemorrhage) is met in analysis of the first 202 patients. Adaptive sample size re-estimation (Mehta and Pocock) will be performed when 240 patients have completed 3 month follow-up (minimum sample size 320, maximum sample size 688).

Read the detailed description

The study is a Multi-Arm Multi-Stage (MAMS), multiregional, multicentre, prospective, randomised, open-label, blinded endpoint (PROBE), controlled seamless phase 2b/3 trial (2 arm with 1:1 randomisation) with adaptive sample size recalculation in patients with stroke due to basilar artery occlusion. Stage 1 will use the surrogate outcome of recanalization without symptomatic intracerebral hemorrhage (sICH) to establish whether proceeding to Stage 2 is warranted. If results in the first n= 202 patients meet success criteria, the trial will seamlessly convert to a phase 3 design using modified Rankin scale 0-1 at 3 months as the primary outcome (minimum n=320 with interim sample size re-estimation at n=240, maximum sample n=688) using the Mehta and Pocock conditional power method. Each regionally-based stratum will be pooled in the final analysis and analysed as a stratification by geographic region. Randomisation of patients within each stratum will be stratified by the investigator's intention to treat with mechanical thrombectomy (or not) and the investigator's intention to treat with alteplase intravenous thrombolysis should the patient be randomised to the control group (or not). Covariate adjusted minimum sufficient balance randomisation will then be applied to control for age, NIHSS and time from onset-to-randomisation (dichotomized as 0-6 hours vs 6-24 hours). The primary objective of the study is to test the hypothesis that the thrombolytic tenecteplase (TNK, 0.25mg/kg) ± mechanical thrombectomy administered within 24 hours after symptoms onset, is superior to current best practice (alteplase, rtPA, 0.9mg/kg or standard care/no lysis ± mechanical thrombectomy) in achieving excellent functional outcome (mRS 0-1) or return to the premorbid modified Rankin Scale at 90 days in patients with acute ischemic stroke due to basilar artery occlusion. Estimated study duration is 5 years. Patients will participate in the trial for 12 months.

03

Conditions studied

  • Basilar Artery Occlusion

Keywords

  • ischemic stroke
  • basilar artery occlusion
  • Stroke
  • Tenecteplase
  • Tissue Plasminogen Activator
  • Cerebrovascular Disorders
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Vascular Diseases
  • Cardiovascular Diseases
  • Fibrin Modulating Agents
  • Molecular Mechanisms of Pharmacological Action
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients presenting with posterior circulation ischemic stroke symptoms due to partial or complete basilar artery occlusion within 24 hours from symptom onset (or clinical deterioration/coma) or the time the patient was last known to be well.
  • Patient's age is ≥18 years
  • Presence of basilar artery occlusion, proven by CT Angiography or MR Angiography. Basilar artery occlusion is defined as 'potentially retrievable' occlusion at the basilar artery. This can be a partial or complete occlusion.
  • Premorbid mRS ≤3 (independent function or requiring only minor domestic assistance and able to manage alone for at least 1 week).
  • Local legal requirements for consent have been satisfied.

Exclusion criteria

Exclusion Criteria:

  • Intracerebral hemorrhage (ICH) or other diagnosis (e.g. tumour) identified by baseline imaging.
  • Posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) \<7 on non-contrast CT, CT Angiography source images or DWI MRI.
  • Significant cerebellar mass effect or acute hydrocephalus.
  • Established frank hypodensity on non-contrast CT indicating subacute infarction.
  • Bilateral extensive brainstem ischemia.
  • Strong suspicion of underlying intracranial atherosclerotic disease (e.g diffuse arterial calcifications, basilar stenosis) or dissection which may require immediate neuro-interventional procedure with intracranial stenting and not benefit from intravenous thrombolysis at investigator's discretion.
  • Pre-stroke mRS of ≥4 (indicating moderate to severe previous disability).
  • Other standard to intravenous thrombolysis.
  • Contraindication to imaging with contrast agents.
  • Clinically evident pregnant women.
  • Current participation in another research drug treatment protocol.
  • Known terminal illness such that the patients would not be expected to survive a year.
  • Planned withdrawal of care or comfort care measures.
  • Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
688 participants (estimated)

Study arms

  • Experimental
    Intravenous tenecteplase (TNK)

    Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds).

    Drug: Tenecteplase

  • Active comparator
    Standard Care (which may include intravenous Alteplase)

    Patients will receive standard of care (no intravenous thrombolytic treatment or intravenous alteplase 0.9mg/kg at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as a bolus and the remainder as an infusion over 1 hour).

    Drug: Standard Care (which may include intravenous Alteplase)

Interventions

  • Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as an intravenous bolus over 5-10 seconds.

  • DrugStandard Care (which may include intravenous Alteplase)

    Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as a bolus and the remainder as an infusion over 1 hour.

06

What researchers measure

Primary outcomes

  1. Modified Rankin Scale (mRS) 0-1 or return to baseline mRS at 90 days

    Modified Rankin Scale (mRS) 0-1 (no disability) or return to baseline mRS (if baseline premorbid mRS 2-3) at 90 days

    Time frame: 90 days

Secondary outcomes

  1. Modified Rankin Scale 0-2 or return to baseline mRS at 90 days

    Proportion of patients with Modified Rankin Scale 0-2 or return to baseline mRS at 90 days

    Time frame: 90 days

  2. Modified Rankin Scale 0-3 or return to baseline mRS at 90 days

    Proportion of patients with Modified Rankin Scale 0-3 or return to baseline mRS at 90 days

    Time frame: 90 days

  3. Ordinal analysis of the mRS at 90 days

    Ordinal analysis of the mRS, merging category 5-6, at 90 days

    Time frame: 90 days

  4. Early clinical improvement

    Proportion of patients achieving early clinical improvement (reduction in acute - 72 hour NIHSS score of ≥8 or 72 hour NIHSS 0-1).

    Time frame: 72 hours

  5. Substantial reperfusion on initial digital subtraction angiography run prior to thrombectomy

    Proportion of patients with complete occlusion at baseline who achieve eTICI 2b/3 on initial digital subtraction angiography run prior to thrombectomy.

    Time frame: Initial angiogram (day 0)

  6. Quality of Life assessment (EQ-5D) - at 90 days and 12 months

    Quality of Life assessment (EQ-5D) - at 90 days and 12 months

    Time frame: 90 days and 12 months

  7. Symptomatic intracerebral hemorrhage (sICH)

    Proportion of patients with sICH defined as parenchymal hemorrhage type 2 (PH2), subarachnoid hemorrhage, and/or intraventricular hemorrhage within 36 of treatment, combined with a neurological deterioration of ≥4 points on the NIHSS from baseline, or leading to death.

    Time frame: 36 hours

  8. All-cause mortality within 90 days

    All-cause mortality within 90 days

    Time frame: 90 days

  9. Modified Rankin Scale (mRS) 5-6 at 90 days

    Proportion of patients with Modified Rankin Scale (mRS) 5-6 at 90 days (severe disability or death)

    Time frame: 90 days

Other outcomes

  1. Intermediate outcome (Stage 1): Partial or complete recanalization of the basilar artery without sICH

    Proportion of patients achieving partial or complete recanalization of the basilar artery on initial digital subtraction angiography (DSA) prior to thrombectomy or repeat CT Angiography (if DSA not performed) without symptomatic intracerebral hemorrhage (sICH). Partial or complete recanalization is defined as reperfusion of ≥50% of the affected territory or absence of retrievable thrombus.

    Time frame: Initial angiogram (day 0)

07

Study locations

13 of 17 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient data will be uploaded to the Virtual Stroke Trials Archive 2 years after the publication of the primary manuscript. Qualified investigators can access data after submission of a project proposal that has been approved by the VISTA steering committee.

Time frame: 2 years after the publication of the primary manuscript.

Access criteria: Qualified investigators can access data after submission of a project proposal that has been approved by the VISTA steering committee.

Data sharing details ↗ · www.virtualtrialsarchives.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for May 2028, 78 months after the start.

Of 31 phase 2/3 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 55. This study's planned 78 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2021
First posted
Nov 3, 2021
StartActual
Nov 29, 2021
Primary completionEst.
May 2028
CompletionEst.
May 2029
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05105633
Lead sponsor
University of Melbourne
Responsible party
Sponsor
First posted
Nov 3, 2021
Start date
Nov 29, 2021
Primary completion
May 2028 (estimated)
Completion
May 2029 (estimated)
Last update
May 6, 2026

Study contacts

Fana Alemseged, MD, PhD
Contact
Fana.Alemseged@unimelb.edu.au
+6193424424
Erin White
Contact
erin.white@florey.edu.au
Bruce Campbell
principal investigator · University of Melbourne
Fana Alemseged
principal investigator · University of Melbourne

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenecteplase

Start the discussion